Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of Stock
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $14.65, for a total transaction of $64,460.00. Following the transaction, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at $10,894,838.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded down $0.15 during trading hours on Thursday, hitting $14.55. The stock had a trading volume of 165,509 shares, compared to its average volume of 230,102. Atara Biotherapeutics, Inc. has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.05). equities research analysts predict that Atara Biotherapeutics, Inc. will post -4 EPS for the current year.
Several research analysts have commented on ATRA shares. Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Jefferies Group reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Canaccord Genuity reaffirmed a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research note on Monday, September 11th. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Finally, ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $24.40.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.